

## **IncellDx Announces the Expansion of HPV OncoTect<sup>®</sup> E6, E7 mRNA by Labco Laboratories Throughout Europe**

MENLO PARK, CA, February 8, 2012 - A key distributor of IncellDx's revolutionary cervical cancer test has signed a definitive agreement to expand the use of HPV OncoTect<sup>®</sup> within one of Europe's largest clinical laboratory networks. The agreement between distributor LABEC Pharma and the Labco system specifies that Labco will now offer IncellDx's HPV OncoTect<sup>®</sup> assay throughout its entire network in Europe. Labco had been offering HPV OncoTect<sup>®</sup> on a limited basis since mid-2010.

The HPV OncoTect<sup>®</sup> assay quantifies the overexpression of E6/E7 mRNA, the cancer-causing genes of HPV, in each cell and the total proportion of cells that are overexpressing E6/E7 mRNA. This information has the promise of providing a more specific indication that an HPV infection is transforming into cervical cancer. HPV OncoTect<sup>®</sup> can be performed directly from routine liquid based cytology samples and provides results in 3<sup>1/2</sup> hours. The HPV OncoTect<sup>®</sup> test is currently CE-IVD marked and available in Europe, South America, and Southeast Asia.

Dr. Bruce Patterson, CEO of IncellDx Inc., said "We are pleased to sign this agreement with Labec, Inc. to supply Labco with HPV OncoTect<sup>®</sup>." "Labco is one of the largest laboratories in Europe and represents an important partner in our continued growth in Europe."

"We are very excited to offer HPV OncoTect<sup>®</sup> in Europe as it helps in the early detection of cervical cancer," said Dr. Luis Izquierdo, Director of Genetics Spain at Labco Diagnostics. Javier de Echevarria, CEO Labec Pharma stated that "HPV OncoTect<sup>®</sup> proves to be the most reliable HPV test available in Europe, and we are happy to be able to expand our offering to our customers."

Headquartered in Brussels, Belgium, Labco currently operates clinical laboratories in Belgium, Germany, Spain, Portugal, France, Italy and the UK. It recently placed €500 million in senior secured notes to fund its continued expansion. LABEC Pharma is IncellDx's exclusive distributor for Spain and Portugal.

*Inceldx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection.*

*Contact: Eric Hass  
Inceldx, Inc.  
650.777.7630*